Public Health

The link between reducing opioid prescriptions and mental health problems

During the opioid epidemic, reducing overdose fatalities has been the main priority for public health campaigners. However, a new study has explored the effects of reducing prescriptions. 

The study, which was carried out by researchers at the University of California, looked at the impact of health care providers reducing opioid prescriptions to treat patients in pain. 

One of the key findings of this study was that, despite practitioners aiming to lower the doses for patients using opioids for pain management, this may cause other issues.

They found that reducing the dosage for these patients could lead to more mental health problems and even an increase in overdoses. 

Researcher Alicia Agnoli said, “Prescribers are in a really difficult position. There are conflicting desires of ameliorating pain among patients while reducing the risk of adverse outcomes related to prescriptions.” 

“Our study showed an increased risk of overdose and mental health crisis following dose reduction. It suggests that patients undergoing tapering need significant support to safely reduce or discontinue their opioids.” 

How to help patients on opioids

For the study, the researchers analyzed the data of over 113,000 patients using opioids to manage their pain, including their hospital records. 

By comparing the records of those that had their doses reduced over a year to those that were kept on the same dosage, they found a link between lower doses and mental health problems. 

Reducing opioid prescriptions resulted in a 70% higher risk of a mental health emergency, with patients more likely to experience drug withdrawal, depression, anxiety, and suicidal thoughts. 

Alicia Agnoli added, “We hope that work will inform a more cautious and compassionate approach to decisions around opioid dose tapering.” 

“Our study may help shape clinical guidelines on patient selection for tapering, optimal rates of dose reduction, and how best to monitor and support patients during periods of dose transition.” 

Claire Robinson

Recent Posts

How the FTC and Congress plan to deal with shrinkflation

With inflation and rising living costs affecting more consumers, the issue of ‘shrinkflation’ is becoming…

16 hours ago

Methylene chloride ban announced by the EPA over cancer risks

The Environmental Protection Agency (EPA) has announced a ban on methylene chloride in products for…

17 hours ago

How is Ozempic affecting consumers’ food shopping habits?

Ozempic and other GLP-1 drugs are usually prescribed to treat diabetes. Recently, the endorsement of…

1 week ago

Dating app sued for sharing personal health information with third parties

Grindr, the world's largest dating app catering to the LGBTQ+ community, now faces legal action…

1 week ago

Serious illnesses reported in two US states due to fake botox injections

At least two states have seen people hospitalised with symptoms resembling botulism after undergoing cosmetic…

3 weeks ago

Amazon announces the latest updates to its use of AI technology

In the last few years, Amazon, like other online retailers, has been experimenting with the…

3 weeks ago